Professional Documents
Culture Documents
Chemotherapy and Targeting Therapy in Colon Cancer
Chemotherapy and Targeting Therapy in Colon Cancer
Chemotherapy and Targeting Therapy in Colon Cancer
in Colon Cancer
Aru W. Sudoyo
Div. Hematology – Medical Oncology
Dept. Internal Medicine
University of Indonesia
Colorectal Cancer: Epidemiology
Data from the United States (2006)[1]
148,610 new cases: third highest cancer incidence
55,170 deaths: second leading cause of cancer-related death in
men, third leading cause in women
Worldwide (2002)[2]
1,023,256 new cases: third highest incidence after lung, breast
cancer
529,020 deaths: fourth overall cause of cancer-related death
after lung, gastric, liver cancer
INDONESIA ? One of 10 most common cancers
P<0.001
clinicaloptions.com/onco
1. Surveillance, Epidemiology, and End Results registry; 2 O’ Connell et al, J Natl Cancer Inst 2004, 96: 1420-25
Evolution of Colorectal Cancer
treatment landscape
Months
30 Median OS
25
20
15
10
5
0
I 85–95%
II 60–80%
Place for
III 30–60% systemic
therapy
IV <5%
Templa
te
9/12/2010 10
copyrig
ht 2005
Adjuvant Therapy
Goals of adjuvant chemotherapy
Target viable and occult tumor cells kan sel tumor
Eradicate tumor cells before refractory to treatment
Risk: benefit
Balance between possibility of cure and tolerance to
side effects
Rectal cancer : +
radiotherapy
Protokol De Gramont @ 2 wks
0.9 p=0.258
0.8 3.8%
p=0.005
0.7
Probability
0.6 7.5%
0.5
0.4
Oxaliplatin
130mg/m2 as a Day 1 8 15 21
2-hour i.v. infusion
Oral capecitabine
1,000mg/m2 Days 1–14 Rest
twice daily
Irinotecan
Day 1 8 15 21
200–350mg/m2
30-minute
i.v. infusion
capecitabine
750–1,250mg/m2 Days 1–14 Rest
twice daily
safety
De Gramont, 2006
Advanced or Metastatic Colorectal Cancer
1st Line
FOLFOX 4 Oxaliplatin 85 mg/m2 IV over 2 hours, day
1; Leucovorin 200 mg/m2 IV over 2 hours, days 1 and
2; 5-FU 400 mg/m2 IV bolus, then 600 mg/m2 IV over
22 hours continuous infusion, day 1 and 2 Repeat
every 2 weeks
FOLFIRI Irinotecan 180 mg/m2 IV over 2 hours, day
1; Leucovorin 400mg/m2 IV over 2 hours prior to 5-FU,
days 1 and 2; 5-FU 400 mg/m2 IV bolus, then 600
mg/m2 IV over 22 hours continuous infusion, days 1
and 2 Repeat every 2 weeks
Bevacizumab 5 mg/kg IV every 2 weeks + 5-FU and
Leucovorin or IFL or FOLFOX or FOLFIRI
Cetuximab irinotecan Cetuximab 400 mg/m2 1st
infusion, then 250 mg/m2 Weekly
Advances in Metastatic Colorectal Cancer
Role of Biologic,
Targeted Therapy
clinicaloptions.com/oncology
Advances in Metastatic Colorectal Cancer
Which Target?
Shc
Grb2
PI3-K Sos-1
Ras
AKT
Raf
MEKK-1
MEK
mTOR MKK-7
ERK
JNK
Which Target?
Shc
Grb2
PI3-K Sos-1
Ras
AKT
Raf
MEKK-1
MEK
mTOR MKK-7
ERK
JNK
clinicaloptions.com/oncology
Advances in Metastatic Colorectal Cancer
Sos-1
PI3-K
Ras
Grb2
Shc
Raf
MEK
MEKK-1
JNK
MKK-7
ERK
AKT
Ras
Grb2
Shc
Raf
MEK
MEKK-1
JNK
MKK-7
ERK
AKT
Angiogenesis
Angiogenesis Lymphangiogenesis Lymphangiogenesis
Angiogenic switch
Results in overexpression
of pro-angiogenic signals,
such as VEGF
PFS estimate
OS estimate
Bevacizumab
0.4 0.4
+ IFL (n=402)
Placebo
+ IFL (n=411)
0.2 HR=0.66 0.2
p<0.001
0.8
Bevacizumab era (2006)
30.6% received bevacizumab
OS estimate
0.6
(n=701)1 23.0
20 21.3
19.9
15
10
0
Bevacizumab +
XELOX/ XELOX/ Oxaliplatin- FOLFOX XELOX FOLFOX XELOX
FOLFOX4 FOLFOX4 based
chemotherapy
1. Saltz, et al. JCO 2008; 2. Arnold, et al. ASCO GI 2010
Note: cross-study comparison 3. Kozloff, et al. Oncologist 2009; 4. Van Cutsem, et al. Ann Oncol 2009
EGFR
Translating Science Into Clinical Practice: Targeted Therapies
EGFR activation
EGF Pathway mediates multiple
processes
Shc
Grb2
PI3K Sos-1
Ras
AKT
Raf
MEKK-1
MEK
mTOR MKK-7
ERK
Adapted from:
Ciardiello F, et al. N Engl J Med. 2008;358:1160-1174. JNK clinicaloptions.com/oncology
Translating Science Into Clinical Practice: Targeted Therapies
Shc
Grb2
PI3K Sos-1
Ras
AKT
Raf
MEKK-1
MEK
mTOR MKK-7
ERK
Adapted from: JNK
Ciardiello F, et al. N Engl J Med. 2008;358:1160-1174. clinicaloptions.com/oncology
Translating Science Into Clinical Practice: Targeted Therapies
EGF Pathway
Angiogenesis Metastasis
TGFα Interleukin-8
bFGF VEGF
Shc
Grb2
Sos-1
PI3K
Ras
MKK-7 MEK
mTOR
JNK ERK
EGFR-Directed Therapeutics:
Clinical Indications
Agent Indication
Gefitinib Locally advanced or metastatic NSCLC
Erlotinib Advanced NSCLC
Advanced pancreatic cancer
Cetuximab Head and neck cancer
mCRC
Panitumumab mCRC
clinicaloptions.com/oncology
Translating Science Into Clinical Practice: Targeted Therapies
Time to Progression OS
100 100
Progression Free (%)
Alive (%)
60 60
40 40
20 20
0 0
0 2 4 6 8 10 12 0 2 4 6 8 10 12 14 16
Months Months
Cunningham D, et al. N Engl J Med. 2004;351:337-345. Copyright ©
2004 Massachusetts Medical Society. All rights reserved. clinicaloptions.com/oncology
Cetuximab (CRYSTAL): OS and PFS in
KRAS wild-type
ORR, % 40 57 –
<0.0001
10
8
6
4
2
0
CRC[1] CRC[2] CRC[3] CRC[4] Pancreatic[5] HNSCC[6]
Study: 9923 0141 BOND
1. Saltz LB, et al. ASCO 2001. Abstract 7. 2. Saltz LB, et al. J Clin Oncol.
2004;22:1201-1208. 3. Cunningham D, et al. N Engl J Med. 2004;351:337-345.
4. Van Cutsem, et al. EORTC/NCI 2004. Abstract 279. 5. Xiong HQ, et al.
J Clin Oncol. 2004;22:2610-2616. 6. Kies MS, et al. ASCO 2002. Abstract 925.
Not all KRAS wild-type mCRC patients
1
will respond to EGFR inhibitors
Possible responders 22–30% (includes response to dose escalation)
PI3KCA MT PTEN null
(all other WT) (all other WT)
~5% ~6%
PI3KCA MT
(all other WT)
~7% PTEN null
(all other WT)
Reason ~10%
unknown
6–8%
KRAS MT
40%
NRAS MT BRAF MT
3–5% 8–10%
Non-responders 70%
In 59% of patients, BRAF, PI3KCA and PTEN mutational status of primary tumour
is not representative of the related metastases2
MT = mutant; WT = wild-type 1. Hawkes, Cunningham. JCO 2010; 2. Cejas, et al. ASCO 2010
Overall Survival
BSC BSC
1980s 6 mo 1980s 12 mo
5-FU/LV Anthracyclines
1990s 10-12 mo
1990s 15-17 mo
18-22+ mo 23+ mo
50 50
First line strategy of metastatic
CRC
Does the patients need (or desire) aggressive
therapy ?
YES~85 NO~15%
%
K-RAS 5FU/Cape±
bev
Unavailable WT MUT
Double + Doublet +
cetuximab Doublet +
bev bev
Doublet +
bevacizumab
PFS benefit of bevacizumab with oxaliplatin-based
therapy confirmed in daily practice
Bevacizumab + XELOX/FOLFOX4
(n=699) 9.4
(NO16966)1
trials
Bevacizumab + XELOX/FOLFOX4
(n=699) 10.4
‘on treatment’* (NO16966)1
0 2 4 6 8 10 12
Median PFS (months)
*Secondary endpoint 1. Saltz, et al. JCO 2008; 2. Hecht, et al. ASCO GI 2008 (poster)
†Large prospective, 3. Reinacher-Schick, et al. ASCO 2008 (poster); 4. Kozloff, et al. ASCO GI 2007 (poster)
observational trials 5. Van Cutsem, et al. Ann Oncol 2009
Treatment strategy in mCRC is driven by
patient assessment
First-line therapy for patients with metastases
XELOX ± bevacizumab
5-FU/LV + bevacizumab
Previously
untreated FOLFOXIRI‡
mCRC
Capecitabine ± bevacizumab
Panitumumab*‡
YES~85 NO~15%
%
K-RAS 5FU/Cape±
bev
Unavailable WT MUT
Double + Doublet +
cetuximab Doublet +
bev bev
Doublet +
bevacizumab
Therapeutic strategy according to
clinical situation and treatment goal
according to German S3 guideline
Liver ± lung metastases Most active combination
Potential resectability after ‘conversion’ Goal: resection cure?
Parameters: RR, pCR?, (OS)